home / stock / xrtx:cc / xrtx:cc news

XRTX:CC News and Press, Xortx Therapeutics Inc. From 04/30/25

Stock Information
Company Name: Xortx Therapeutics Inc.
Stock Symbol: XRTX:CC
Market: TSXVC
Website: xortx.com
Menu
Get XRTX:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
XRTX:CC - XORTX Provides Update on FDA Type B Meeting Request

● XORTX will focus on key steps to advance a NDA filing for Gout indication ● CALGARY, Alberta, April 30, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage cl...
XRTX:CC - XORTX Announces Grant of European Patent

CALGARY, Alberta, April 28, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kid...

XRTX:CC - XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

CALGARY, Alberta, April 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disea...

XRTX:CC - XORTX Announces Update for Discussion with the FDA

● Type B Meeting Discussion to Accelerate XRx-026 for Gout to NDA ● CALGARY, Alberta, March 19, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceuti...
XRTX:CC - XORTX Commences Gout Program NDA Discussions with the FDA

● Type C Meeting Requested to Accelerate XRx-026 for Gout to NDA ● CALGARY, Alberta, Feb. 24, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA), a late stage clinical pharmaceutic...

XRTX:CC - XORTX to Present at Microcap Conference

CALGARY, Alberta, Jan. 29, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disea...

XRTX:CC - XORTX Announces Change of Auditor

CALGARY, Alberta, Jan. 17, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney diseas...
XRTX:CC - XORTX Adds Late Stage Gout Program to Pipeline

CALGARY, Alberta, Jan. 06, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney diseas...

Previous 10 Next 10